New KRAS-Targeting Drug Nearly Doubles Survival in Pancreatic Cancer Trial
A new pancreatic cancer trial has drawn serious attention because the survival gain is unusually large for a disease where progress often comes in small steps. Daraxonrasib, an oral RAS-targeting drug from Revolution Medicines, helped patients with previously treated metastatic pancreatic ductal adenocarcinoma live a median of 13.2 months, compared with 6.7 months for patients … Read more